PHA-022121

· Pharvaris Netherlands B.V.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for PHA-022121, covering 2025-07-30 to 2026-08-17. Get the full timeline:

Most recent: Clinical Trial Results: Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II [Phase 2]

See pricing